<DOC>
	<DOCNO>NCT02807974</DOCNO>
	<brief_summary>To examine antihypertensive effect safety administration CS-3150 combination ARB ACE inhibitor hypertensive patient type 2 diabetes albuminuria .</brief_summary>
	<brief_title>Study CS-3150 Hypertensive Patients With Type 2 Diabetes Albuminuria</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<criteria>Male female subject age 20 80 year informed consent Subjects type 2 diabetes albuminuria ( urine albumintocreatinine ratio ≥ 30 , &lt; 1000 mg/g/Cr ) Subjects hypertension ( Sitting SBP ≥ 140 mmHg , &lt; 180 mmHg Sitting DBP ≥ 80 mmHg , &lt; 110 mmHg Treatment ARB ACE inhibitor eGFR ≥ 30 mL/min/1.73m^2 Secondary hypertension malignant hypertension Type 1 diabetes Secondary glucose intolerance Diagnosed nondiabetic nephropathy Serum potassium level &lt; 3.5 ≥ 4.8 mEq/L</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypertension Type 2 Diabetes Albuminuria</keyword>
	<keyword>Diabetic nephropathy</keyword>
	<keyword>Diabetic renal disease</keyword>
	<keyword>Albuminuria</keyword>
	<keyword>Mineralocorticoid receptor antagonist</keyword>
</DOC>